Abstract 3127
Background
In humans Tregs lack a unique phenotypic marker and Foxp3 expression in cluster of differentiation (CD) 4+CD25+ or CD4+CD25high T lymphocytes is commonly used for their characterization. In early colorectal cancer, the presence of Tregs in CRC tumour tissue has been associated with favourable prognosis. However, the prognostic role of circulating Tregs in CRC patients and especially in the metastatic setting is not yet clear.
Methods
We collected peripheral blood from 57 patients with mCRC before initiation of first line chemotherapy. Samples were analysed with multicolour flow cytometry using monoclonal antibodies against CD3, CD4, CD25, and FoxP3. The ratio of FoxP3 positive cells within the CD3+CD4+CD25high lymphocytic subpopulation (F/H ratio) was measured and quartile analysis according to this ratio was carried out. Overall survival was calculated from initiation of first line chemotherapy to death or last follow up. Median OS (mOS) was compared between the highest quartile and the rest using the Breslow (Generalized Wilcoxon) method. Ratios were compared between groups with the Mann Whitney U-test. Statistics were analyzed with SPSS and flow cytometry data with Kaluza 2.1.
Results
The median F/H ratio was 0,08 (Interquartile range 0,018-0,34) with a distribution skewed to the right (range 0 to 0.85). For each quartile mOS is shown in the table. The mOS for the highest quartile was 8 months (m) (95% Confidence Interval(CI) 0 - 20.6m) and 25m for the rest (95% CI 18.2m-31.8m)(p = 0.03). No difference was observed in F/H ratio in different groups according to KRAS/NRAS mutations’ status, prior adjuvant chemotherapy, performance status or sidedness of primary site.Table:
610P
Quartile | F/H ratio (range) | n | mOS (m) | mOS(m) | p |
---|---|---|---|---|---|
1st | 0-0,018 | 14 | 24 | 25 | |
2nd | 0,0181-0,08 | 15 | 34 | ||
3rd | 0,0810-0,34 | 15 | 24 | ||
4th | 0,3410-0,85 | 13 | 8 | 0.03 |
Conclusions
The F/H ratio in patients with mCRC is spread over a wide range of values with the majority below 0.1. High values (>0.34) seem to have prognostic significance and be associated with worse outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical School, University of Crete.
Funding
Hellenic Oncology Research Group, Medical School, University of Crete.
Disclosure
Z. Zafeiriou: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Bristol. A. Koutoulaki: Full / Part-time employment: Genesis Pharma. V. Georgoulias: Travel / Accommodation / Expenses: Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
3006 - Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study.
Presenter: Violaine Randrian
Session: Poster Display session 2
Resources:
Abstract
3697 - The expression of Versican and its role in pancreatic neuroendocrine tumor
Presenter: Zhao Sun
Session: Poster Display session 2
Resources:
Abstract
6073 - Characteristics of patients with thyroid carcinoma in the united states
Presenter: Dina El-Habashy
Session: Poster Display session 2
Resources:
Abstract
2124 - The discrimination of pituitary adenomas and craniopharyngioma on MRI: from image features to texture features
Presenter: Hanyue Xu
Session: Poster Display session 2
Resources:
Abstract
3786 - Proportion of Peripheral Lymphocyte Subsets Correlates with the Progression-free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumor Patients
Presenter: Yitao Gong
Session: Poster Display session 2
Resources:
Abstract
2263 - Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma
Presenter: Enas Elkhouly
Session: Poster Display session 2
Resources:
Abstract
4386 - SILVELUL Project: Immunohistochemical panel analyses as potential predictive and prognostic factors in Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
Presenter: Ana De Jesus-Acosta
Session: Poster Display session 2
Resources:
Abstract
2302 - Carcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French Group of Endocrine Tumors (GTE)
Presenter: Kathleen Dekeister Geoffroy
Session: Poster Display session 2
Resources:
Abstract
5749 - Safety of high doses of somatostatin analogs in well differentiated NENs in elderly
Presenter: Massimiliano Cani
Session: Poster Display session 2
Resources:
Abstract
3931 - Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract